|
[news 2003
- 2004]
GB
Therapeutics obtains full-time CEO
KINGSTON, ON -- John Molloy, Chairman of the Board of
GB Therapeutics and President & CEO of PARTEQ Innovations,
is pleased to announce the appointment of Anthony Giovinazzo
as full-time President & CEO of GB Therapeutics.
Mr. Giovinazzo comes to GB Therapeutics from Prescient
NeuroPharma Inc. (TSX-V:PRE), where he was President
& CEO from 1998-2002. While there he led the merger
of Neurotrophic Bioscience Inc. (NTB) and IGT Pharma
Inc. to create Prescient. He oversaw the identification
of the company's first clinical candidate and
completed the licensing of a Phase II chemotherapeutic
for US$18.75 million in milestone payments.
"Mr. Giovinazzo's agreement to join GB Therapeutics
and his input into its clinical direction helped catalyze
the current investor commitment to GB Therapeutics,"
says Mr. Molloy. "With 24 years of experience in
investment and biopharmaceutical management he brings
strong leadership in guiding the company through this
crucial phase of its evolution."
Prior to his appointment at NTB, Mr. Giovinazzo was
Executive Vice-President of Nova Molecular Inc., a pioneer
in the pharmacogenomics of central nervous system (CNS)
diseases. Previously he was President of the Neuroscience
Partners Fund and a Vice- President and Partner at MDS
Capital Corp. Mr. Giovinazzo serves as Chairman of Dynamic
BioSciences, and also is a Director of the Board for
the Toronto Biotechnology Initiative.
Mr. Molloy also wishes to thank Mr. Ian Anderson for
his vital contribution over the last year as interim
CEO.
About GB Therapeutics Ltd.
GB Therapeutics is at the forefront of new research
relating to the cell-protecting properties of nitric
oxide (NO). Founded in 1997 on research breakthroughs
by leading scientists at Queen's University, in
partnership with PARTEQ Innovations, GB Therapeutics
has developed a product pipeline of novel nitrates that
hold exciting promise for the treatment of mild cognitive
impairment, vascular dementia, epilepsy and pain, and
for cardioprotection. The company's product pipeline
includes an Alzheimer's product candidate that
is completing pre-clinical studies and expected to begin
human safety testing in early 2004.
GB Therapeutics offers breakthrough technology with
a clear competitive advantage. A comprehensive patent
portfolio protects the company's nitrate library of
more than 200 compounds that have resulted in five patents
issued and 10 patents pending worldwide.
Contact:
John Molloy
Chairman, GB Therapeutics Ltd. Board of Directors
President & CEO, PARTEQ Innovations
P: 613. 533.2342
F: 613. 533.6853
Email: jmolloy@parteqinnovations.com
Anthony Giovinazzo
President & CEO
GB Therapeutics Ltd.
P: 416-723-2549
Email: agiovinazzo@gbtherapeutics.com
GB Therapeutics Ltd.
Research Centre
P: 613. 545.1239
F: 613. 533.6853
www.gbtherapeutics.com
|
